Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Clinical trials sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New anemia drug candidate put to the test against market leader Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1 Completed 1

Can a new drug match a standard anemia treatment for dialysis patients?

Disease control Completed

This trial is testing whether a new version of darbepoetin alfa works as well as the standard treatment (Aranesp) for anemia in people with chronic kidney disease who are on dialysis. Participants will receive either the new drug or Aranesp by injection every other week for 24 we…

Phase 3 • Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company • Aim: Disease control

Last updated Aug 23, 2026 00:00 UTC